GET DAILY SIGNALSSELLAS Life Sciences (SLS) Readies Q3 2026 Earnings Report as REGAL Trial Approaches Final Analysis
Key Takeaways
- SELLAS Life Sciences Group (SLS) is expected to report third-quarter 2026 results in mid-November, with Wall Street consensus projecting a net loss of approximately $0.05 per share.
- As a late-stage clinical biopharmaceutical company, SELLAS generates no product revenue, so investors will focus on net loss, research and development spending, and its cash runway rather than top-line sales.
- The pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML, a cancer of the blood and bone marrow) remains the single most important catalyst, with the final analysis triggered once the pre-specified 80th event occurs.
- Topline data from the Phase 2 trial of SLS009, a CDK9 inhibitor, in newly diagnosed AML patients is expected in the fourth quarter of 2026.
- For more detail on the ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover Trending AI Robots to see how algorithmic trading strategies are navigating the current market.
Why the Quarter Matters for SELLAS
SELLAS Life Sciences Group is a clinical-stage developer of novel cancer immunotherapies, led by galinpepimut-S (GPS) and SLS009. Because the company has no commercialized products, quarterly earnings releases function less as traditional income statements and more as progress reports on clinical execution and financial health. I focus on how quickly the company is spending on its two lead programs, whether its cash position can fund operations through major data readouts, and any updates on trial timelines. With the Phase 3 REGAL trial of GPS in AML nearing its final analysis and SLS009 advancing toward topline data, this report arrives at a pivotal moment for the company's clinical pipeline and long-term value proposition. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Expect
Analysts expect SELLAS to report a net loss of roughly $0.05 per share for the third quarter of 2026, an improvement from the $0.06 per share loss reported in the same period a year earlier. In the second quarter of 2026, the company posted a net loss of approximately $9.6 million, or $0.05 per share, slightly wider than consensus estimates. SELLAS has beaten consensus EPS expectations in seven of its last eight quarters, though the absence of revenue means the focus stays on expense discipline and cash management.
Key metrics investors will monitor include research and development (R&D) expenses, general and administrative costs, the year-end cash balance, and any commentary on the pace of spending ahead of a potential Biologics License Application for GPS. Historically, SELLAS shares have reacted more to clinical trial announcements than to the headline loss figure itself.
Market Sentiment Ahead of the Release
Sentiment heading into the report is dominated by anticipation of the REGAL trial readout rather than the quarterly loss figure. SELLAS shares have historically shown elevated volatility around clinical milestones, and the market is closely watching for confirmation that the 80th event has been reached and that the final analysis is underway. Because the company remains blinded to trial outcomes, any guidance on timing could move the stock regardless of the financial results. Key risks include potential delays in the REGAL readout, faster-than-expected cash burn, and the possibility of dilutive capital raises as the company approaches critical data milestones.
What to Watch After the Report
Following the third-quarter report, investors should focus on several clinical and financial signals. First, any update on the REGAL trial's progress toward the 80th event will be the most consequential item. Management has indicated it will announce when the event occurs, after which a database lock and blinded review precede the topline readout.
Second, watch for commentary on SLS009, including enrollment progress in the Phase 2 trial in newly diagnosed AML patients and confirmation that topline data remains on track for the fourth quarter of 2026. Early preclinical work also points to a potential expansion into advanced pancreatic cancer, which could broaden the pipeline's addressable market.
Third, monitor the company's cash runway. SELLAS reported roughly $107 million in cash and equivalents as of March 31, 2026, supplemented by warrant exercise proceeds, and management has said it expects to fund operations for at least twelve months. Finally, keep an eye on R&D spending trends, which are likely to rise as the company prepares for a potential regulatory filing for GPS.
Using AI Tools in My Research Process
In my analysis of clinical-stage names like SELLAS, I often turn to Tickeron’s AI Screener to quickly filter for similar biotech stocks based on volatility patterns, cash metrics, and technical signals. It helps surface comparable ideas without spending hours on manual reviews, and I find the customizable filters useful when cross-checking pipeline timelines against peers. The tool has become a regular part of how I prepare for earnings in this sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SLS's RSI Oscillator ascends from oversold territory
The RSI Oscillator for SLS moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 19 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SLS as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for SLS turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SLS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.498). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals
Industry Biotechnology
Advertisement